<DOC>
	<DOCNO>NCT00941252</DOCNO>
	<brief_summary>The present primary therapy cervical intraepithelial neoplasia ( CIN ) grade 3 persistent CIN 2 represent conisation . Surgical treatment cause perioperative ( infection , bleed 5-10 % ) postoperative ( increase risk preterm labor ) complication , well incomplete resection ( 20 % ) risk recurrence 5-17 % . Imiquimod immunomodulating drug , report effective human papilloma virus-related disease , vulvar intraepithelial neoplasia ( VIN ) , vaginal intraepithelial neoplasia ( VAIN ) , anal intraepithelial neoplasia ( AIN ) . The present randomise , placebo control , double blind study evaluate efficacy topical treatment imiquimod 16 week 60 patient histologically confirm CIN 2/3 .</brief_summary>
	<brief_title>ITIC ( Imiquimod Therapy Cervical Intraepithelial Neoplasia ) -Trial</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Caucasian woman age 18 year old proven HPVassociated CIN 2/3 Colposcopy fully visible transformation zone lesion Safe Contraception Signed Informed Consent Negative urine pregnancy test Able communicate well investigator , understand comply requirement study Signed write informed consent Women pregnant lactate become pregnant conduct study Symptoms clinically relevant illness 3 week first study day History hypersensitivity trial drug drug similar chemical structure Participating another clinical trial within 30 day Malignancy Immunosuppression ( medication , illness ) HIV Hepatitis infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>